drugset
drugset / Trial / NCT05841160

Thorough QT/QTc Study to Evaluate the Effects of Ecopipam (EBS-101) on Cardiac Repolarization

NCT05841160 ↗

Phase 1 Completed 29 enrolled Emalex Biosciences Inc. Clario · collabPPD Development, LP · collab
RandomizedCrossoverQuadruple-blindBasic science

Summary

THOROUGH QT/QTc STUDY TO EVALUATE THE EFFECTS OF ECOPIPAM (EBS-101) ON CARDIAC REPOLARIZATION

Timeline

Start
2023-03-15
Primary completion
2023-05-07
Completion
2023-05-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Ecopipam Small molecule 200 mg Oral
Subject Ecopipam Small molecule 600 mg Oral
Comparator Moxifloxacin Small molecule 400 mg Oral

Indications

No indication recorded.